18f-Fluorodeoxyglucose (FDG) PET/CT After Two Cycles of Neoadjuvant Therapy May Predict Response in HER2-negative, but Not in HER2-positive Breast Cancer

Oncotarget - United States
doi 10.18632/oncotarget.5001
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer

Journal of Breast Disease
2018English

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

New England Journal of Medicine
Medicine
2012English

Current Neoadjuvant Treatment Options for HER2 Positive Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2011English

Dynamic Changes in CD44v-positive Cells After Preoperative Anti-Her2 Therapy and Its Correlation With Pathologic Complete Response in HER2-positive Breast Cancer

Oncotarget
Oncology
2018English

Anti-Her2 CD4+ T-Helper Type 1 Response Is a Novel Immune Correlate to Pathologic Response Following Neoadjuvant Therapy in HER2-positive Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2015English

Targeted Therapy for HER2 Positive Breast Cancer

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Prognostic Value of Tumor Heterogeneity on 18f-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients Receiving 500 Mg Fulvestrant: A Retrospective Study

Scientific Reports
Multidisciplinary
2018English

Positive Response to Neoadjuvant Cyclophosphamide and Doxorubicin in Topoisomerase II Nonamplified/Her2/Neu Negative/Polysomy 17 Absent Breast Cancer Patients

Cancer Management and Research
Oncology
2010English

Neoadjuvant Treatment of HER2-positive Breast Cancer: Should Therapy Differ Based on Hormone Receptor Status?

Therapeutic Advances in Medical Oncology
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy